Evolution of the Average Target: Rani Therapeutics Holdings, Inc.

Evolution of the Target Price: Rani Therapeutics Holdings, Inc.

Changes in Analyst Recommendations: Rani Therapeutics Holdings, Inc.

fe68344100b08d2ec6129d95617449.3ciTHz2f6XUcEiiRNjDrb5Meu-n2bQnWm2QTQavFynM.qJ3VKGSvvA1_Kkr_b3u-AuVTwpuMPTmeyiZQO-CMhTG6nadAZ_afQEZbEA~4c2d4dc076220de349a0972731a982b2
08-18 Chardan Initiates Rani Therapeutics Holdings at Buy With $6 Price Target MT
20/10/25 Maxim Adjusts Rani Therapeutics Price Target to $10 From $5, Maintains Buy Rating MT
17/10/25 Top Midday Gainers MT
16/05/25 Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating MT
02/08/24 Oppenheimer Initiates Rani Therapeutics Holdings at Outperform With $17 Price Target MT
14/06/24 Maxim Starts Coverage on Rani Therapeutics With Buy Rating, $15 Price Target MT
16/05/24 UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating MT
07/05/24 HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating MT
27/03/24 Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating MT
25/03/24 HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating MT
10/11/23 Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating MT
09/11/23 HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating MT
14/08/23 HC Wainwright Adjusts Price Target on Rani Therapeutics to $20 From $22, Keeps Buy Rating MT
07/12/22 Wedbush Lifts Rani Therapeutics Holdings' Price Target to $20 From $19, Keeps Outperform Rating MT
11/10/22 UBS Initiates Coverage on Rani Therapeutics With Buy Rating, $15 Price Target MT
29/09/22 Wedbush Adjusts Rani Therapeutics Holdings Price Target to $19 From $17, Maintains Outperform Rating MT
12/08/22 Wedbush Adjusts Price Target on Rani Therapeutics Holdings to $17 From $28, Keeps Outperform Rating MT
27/07/22 HC Wainwright Initiates Rani Therapeutics Holdings at Buy With $22 Price Target MT
13/06/22 Wedbush Starts Rani Therapeutics Holdings at Outperform With $28 Price Target MT
25/08/21 Rani Therapeutics : Canaccord Genuity Starts Rani Therapeutics Holdings at Buy With $29 Price Target MT
25/08/21 Rani Therapeutics : BTIG Starts Rani Therapeutics Holdings at Buy With $24 Price Target MT
24/08/21 Rani Therapeutics : Cantor Fitzgerald Starts Rani Therapeutics Holdings at Overweight with $23 Price Target MT
24/08/21 Rani Therapeutics : Stifel Starts Rani Therapeutics Holdings at Buy with $24 Price Target MT
24/08/21 Rani Therapeutics : BofA Securities Starts Rani Therapeutics Holdings at Buy with $23 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+848.37%
+15.19%
+22.02%
+9.85%
+68.92%
+18.94%
+7.76%
+20.98%
-7.69%
+32.69%
Average +103.70%
Weighted average by Cap. +21.24%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7592USD
Average target price
7.200USD
Spread / Average Target
+848.37%
High Price Target
11.00USD
Spread / Highest target
+1,348.89%
Low Price Target
5.000USD
Spread / Lowest Target
+558.59%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. RANI Stock
  4. Consensus Rani Therapeutics Holdings, Inc.